High Sensitivity C-Reactive Protein Values Do Not Reliably Predict the Severity of Histological Changes in NAFLD [4]

Hepatology

Volumn 39, Issue 5, 2004, Pages 1458-1459

  Hui, Jason M ^a,b   Farrell, Geoffrey C ^a,b   Kench, James G ^b   George, Jacob ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BODY MASS; CLINICAL FEATURE; DISEASE SEVERITY; HISTOLOGY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LETTER; LIVER CELL; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY;

C-REACTIVE PROTEIN; FATTY LIVER; HUMANS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 2342462456     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20223     Document Type: Letter

References (10)

1. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
2. Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J 1999;20:954-959.
3. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive Protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391-397.
4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
5. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. HEPATOLOGY 1995;22:1714-1719.
6. Rothkrantz-Kos S, Schmitz MP, Bekers O, Menheere PP, van Dieijen-Visser MP. High-sensitivity C-reactive protein methods examined. Clin Chem 2002;48:359-362.
7. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-1812.
8. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
9. Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European Whites. Circulation 2001;104:145-150.
10. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-235.